局所疼痛緩和のアメリカ市場

Allied Market Researchが発行した調査報告書(AMR9AG082)
◆英語タイトル:U.S. Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), Formulation (Cream, Gel, Spray, Patch, and Others), and Distribution Channel (Pharmacies & Drug Stores, E-commerce, and Retail & Grocery Stores): Opportunity Analysis and Industry Forecast, 2018-2025
◆商品コード:AMR9AG082
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2019年6月29日
◆ページ数:128
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アメリカ
◆産業分野:ライフサイエンス
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥574,590見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥690,150見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥962,465見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The U.S. topical pain relief market size was valued at $2,324 million in 2017, and is projected to reach $3,730 million by 2025 at a CAGR of 6.0% from 2018 to 2025.
Pain is a distressing feeling, which is usually caused by intense or damaging stimuli. Pain is most prevalent symptom associated with most of chronic conditions. Pain management involves the employment of medications or analgesics and therapies to treat several pain conditions. Whenever, these medications are applied directly to the skin they are known as topical pain relief. These analgesics include non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, and opioids. These medications are present as creams, ointments, gels, and transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.

Market dynamics

The growth of the U.S. topical pain relief market is majorly driven by increase in prevalence of arthritis and other bone-related conditions, diabetic neuropathy, leading to pain. Other factors that boost the market growth include rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the U.S., and increase in demand for topical pain relief by sports players. However, factors such as topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that hamper the market growth. Conversely, the development of online platform for the topical therapeutics is expected to provide lucrative growth opportunities for the market.

Market segmentation

The U.S. topical pain relief market is segmented based on therapeutic class, type, formulation, and distribution channel. On the basis of therapeutic class, the market is segmented into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. Non-opioids segment accounted for the largest U.S. topical pain relief market share in 2017, and is expected to continue this trend throughout the forecast period owing to high preferability and easy availability of non-opioids drugs.

By type, the U.S. topical pain relief market is segmented into prescription pain relief and over-the-counter (OTC) relief. Over-the-counter pain relief segment accounted for the largest market share in 2017 due to easy availability and high demand for topical pain relief products by sportsperson. Based on formulation, the market is classified into cream, gel, spray, patch, and others. Cream-based pain relief segment accounted for the largest market share in 2017 owing to high availability of these products with high success rate and lesser side effects. On the other hand, patch pain relief segment is expected to grow at a CAGR of 7.6% during the forecast period.

The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores. Pharmacies & drug stores are the major revenue contributors in the U.S. topical pain relief market due to higher presence and wide availability of drugs. On the other side, e-commerce segment is anticipated to exhibit fastest U.S. topical pain relief market growth during the forecast period owing to higher digital literacy among the population. Moreover, these pharmacies offer various advantages such as fewer expenses, more convenience, price comparisons, and easy access to patient reviews, which drive the market growth of this segment.

The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A.

Other players (these players are not profiled in the report and the same can be included on request) in the value chain include Troy Healthcare, LLC, Emami Group, Chattem, Inc., Exzell Pharma, and Performance Health Technologies, Inc.

Key Benefits for US topical pain relief market:
The study provides an in-depth analysis of the current U.S. topical pain relief market trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the U.S. topical pain relief market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a U.S. scale are provided.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
US topical pain relief Key market segments:
By Therapeutic Class
Non-opioids
Non-steroidal Anti-Inflammatory Drugs (NSAIDS)
Methyl Salicylate
Capsaicin
Lidocaine
Other Non-opioids
Opioids
Buprenorphine
Fentanyl
By Type
Prescription Pain Relief
Over-the-counter (OTC) Pain Relief
By Formulation
Cream
Gel
Spray
Patch
Others
By Distribution Channel
Pharmacies & Drug Stores
E-commerce
Retail & Grocery Stores

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines

3.4.2. Restraints

3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief is characterized by unpleasant odor

3.4.3. Opportunities

3.4.3.1. Emergence of online pharmacy

3.4.4. Impact analysis

3.5. U.S. patent analysis by year (2014-2019)

CHAPTER 4: U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Non-opioids

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)

4.2.2.1.1. Market size and forecast

4.2.2.2. Methyl salicylates

4.2.2.2.1. Market size and forecast

4.2.2.3. Capsaicin

4.2.2.3.1. Market size and forecast

4.2.2.4. Lidocaine

4.2.2.4.1. Market size and forecast

4.2.2.5. Other non-opioids

4.2.2.5.1. Market size and forecast

4.3. Opioids

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Buprenorphine

4.3.2.1.1. Market size and forecast

4.3.2.2. Fentanyl

4.3.2.2.1. Market size and forecast

CHAPTER 5: U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cream

5.2.1. Market size and forecast

5.3. Gel

5.3.1. Market size and forecast

5.4. Spray

5.4.1. Market size and forecast

5.5. Patch

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

CHAPTER 6: U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription pain relief

6.2.1. Market size and forecast

6.3. Over-the-counter pain relief

6.3.1. Market size and forecast

CHAPTER 7: U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmacies & drug stores

7.2.1. Market size and forecast

7.3. e-Commerce

7.3.1. Market size and forecast

7.4. Retail & grocery stores

7.4.1. Market size and forecast

CHAPTER 8: COMPANY PROFILES

8.1. AdvaCare Pharma

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio

8.2. GlaxoSmithKline plc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Johnson & Johnson

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance

8.4. Nestlé S.A.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Novartis AG

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance

8.6. Pfizer Inc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. Reckitt Benckiser Group plc

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Sanofi

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Sun Pharmaceutical Industries Ltd.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. Topical BioMedics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 01. U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS, 2017–2025 ($MILLION)
TABLE 02. U.S. TOPICAL NON-OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 03. U.S. TOPICAL OPIOIDS MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 04. U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION, 2017–2025 ($MILLION)
TABLE 05. U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE, 2017–2025 ($MILLION)
TABLE 06. U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL, 2017–2025 ($MILLION)
TABLE 07. ADVACARE: COMPANY SNAPSHOT
TABLE 08. ADVACARE: BUSINESS SEGMENTS
TABLE 09. ADVACARE: PRODUCT PORTFOLIO
TABLE 10. GSK: COMPANY SNAPSHOT
TABLE 11. GSK: OPERATING SEGMENTS
TABLE 12. GSK: PRODUCT PORTFOLIO
TABLE 13. J&J: COMPANY SNAPSHOT
TABLE 14. J&J: OPERATING SEGMENTS
TABLE 15. J&J: PRODUCT PORTFOLIO
TABLE 16. NESTLÉ: COMPANY SNAPSHOT
TABLE 17. NESTLÉ: OPERATING SEGMENTS
TABLE 18. NESTLÉ: PRODUCT PORTFOLIO
TABLE 19. NOVARTIS: COMPANY SNAPSHOT
TABLE 20. NOVARTIS: OPERATING SEGMENTS
TABLE 21. NOVARTIS: PRODUCT PORTFOLIO
TABLE 22. PFIZER: COMPANY SNAPSHOT
TABLE 23. PFIZER: OPERATING SEGMENTS
TABLE 24. PFIZER: PRODUCT PORTFOLIO
TABLE 25. RB: COMPANY SNAPSHOT
TABLE 26. RB: OPERATING SEGMENTS
TABLE 27. RB: PRODUCT PORTFOLIO
TABLE 28. SANOFI: COMPANY SNAPSHOT
TABLE 29. SANOFI: OPERATING SEGMENTS
TABLE 30. SANOFI: PRODUCT PORTFOLIO
TABLE 31. SUN PHARMA: COMPANY SNAPSHOT
TABLE 32. SUN PHARMA: OPERATING SEGMENTS
TABLE 33. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 34. TOPICAL BIOMEDICS: COMPANY SNAPSHOT
TABLE 35. TOPICAL BIOMEDICS: OPERATING SEGMENTS
TABLE 36. TOPICAL BIOMEDICS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. U.S. TOPICAL PAIN RELIEF MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. ESTIMATED AND PROJECTED NUMBER OF ADULTS WITH DOCTOR-DIAGNOSED ARTHRITIS IN THE U.S., 2000-2040 (MILLION)
FIGURE 05. NUMBER OF ELDERLY POPULATION (ADULT 65+) IN THE U.S., 2016-2060 (MILLION)
FIGURE 06. IMPACT ANALYSIS
FIGURE 07. U.S. PATENT ANALYSIS, BY YEAR
FIGURE 08. GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 09. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 10. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 11. J&J: REVENUE, 2016–2018 ($MILLION)
FIGURE 12. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 13. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 14. NESTLÉ: REVENUE, 2016–2018 ($MILLION)
FIGURE 15. NESTLÉ: REVENUE SHARE BY OPERATING SEGMENT, 2018 (%)
FIGURE 16. NESTLÉ.: REVENUE SHARE BY REGIONREGION, 2018 (%)
FIGURE 17. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 19. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 20. PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 21. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 22. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 23. RB: REVENUE, 2016–2018 ($MILLION)
FIGURE 24. RB: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 25. RB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 26. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 27. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 28. SANOFI: REVENUE SHARE BY REGIONREGION, 2018 (%)
FIGURE 29. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 30. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31. SUN PHARMA: REVENUE SHARE BY REGION, 2018 (%)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 局所疼痛緩和のアメリカ市場(U.S. Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), Formulation (Cream, Gel, Spray, Patch, and Others), and Distribution Channel (Pharmacies & Drug Stores, E-commerce, and Retail & Grocery Stores): Opportunity Analysis and Industry Forecast, 2018-2025)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆